MedTrace Logo

EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension

NCT02092818 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1316

Last updated 2019-06-19

No results posted yet for this study

Summary

In accordance with the regulatory guidance this registry has been designed to collect information about the long-term safety of Adempas in real clinical practice outside the regulated environment of a controlled clinical study.

Conditions

  • Hypertension, Pulmonary

Interventions

DRUG

Riociguat (Adempas, BAY63-2521)

The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP)

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2018-03-31
Completion
2018-06-29

Countries

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Canada
  • Colombia
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Portugal
  • Russia
  • Saudi Arabia
  • Slovakia
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02092818 on ClinicalTrials.gov